Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerAnti-angiogenic therapies for metastatic colorectal cancerAnti-angiogenic therapy for metastatic colorectal cancerTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaAntiangiogenic mechanisms and factors in breast cancer treatmentEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewThe role of vascular endothelial growth factor a polymorphisms in breast cancerLessons learned from the bevacizumab experienceAnti-vascular endothelial growth factor therapy in breast cancerThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsBevacizumab treatment for advanced breast cancerBevacizumab in ovarian cancer: A critical review of phase III studiesAngiogenesis and Antiangiogenesis in Triple-Negative Breast cancerRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabA novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNAUnraveling the microenvironmental influences on the normal mammary gland and breast cancerPhase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsIncreased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Phase II open-label study of sunitinib in patients with advanced breast cancer.Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review studySurvival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
P2860
Q24202199-4F118308-7C9F-4377-B0AA-610AE990C8EAQ24241813-0812229E-6B31-479B-A414-19BFBA4699FFQ24243297-EE344AE1-EB0F-4A1C-9074-7C204FC70EE6Q26747666-2D426684-F83C-46DF-B15A-D750CE1E65D6Q26751226-E67C5C71-C1F5-4288-9F94-86573B249E99Q26786618-EBB977DE-1A10-49C6-B2C6-7870F63C78AAQ26822432-5F34D8CC-A3C2-47F7-A078-93F02FCB84CAQ26824086-E95D5779-5BAF-417E-B9F2-C15BB434BC41Q26851522-0E9CA456-9B61-463A-BB5D-D8DE2282F490Q26852509-7CAE79D2-7216-40F1-A1C7-FE469209C8D6Q26999473-19579C0A-013F-4CE3-8415-BC7A52F0AE4EQ27011540-702D4203-BC33-418C-A1DA-4454DB1CC073Q27027498-2B29FA00-A626-4DBF-8CC4-2B15076E954DQ28076188-4C1BDFC2-D2DC-45CF-B992-2094538AA202Q28079013-3BF5A0D2-5559-4BBA-B571-40F56FE174F8Q28087776-49CA5D42-96C9-48BC-B45F-7DD2659747D3Q28219257-B1FA536D-E46A-4D55-A7D2-11B1455673B9Q28472818-6DE7CF06-899E-4105-8BFF-B9FE336D419DQ28473677-D8AF915B-9337-422D-93FA-21459F5EE10EQ28555102-D5214665-8488-4C13-ACB4-C487D9FDF64FQ28749085-787A6EC4-6C10-4048-9419-8DFD23BA737EQ30248296-D3B03BA7-ECC4-4BBD-AE83-148A70D10F64Q30249335-07778D73-42D7-4E8F-A199-9CE1011DB67EQ30317067-FAB51846-3FB5-4B4D-A5C9-7291C886C53FQ30358961-16D5A007-2468-4E2C-B58A-97CDE7FFB229Q30390845-E18DFDAD-AE8A-4E87-9A79-DBA6A7E1A054Q31060162-8EF645AD-CFA7-4AC7-B379-77CD9E4F025CQ31102468-A4971885-D72D-481E-9969-08E9370CFA08Q31152878-B9BF2545-45CE-483E-B1BE-38C0CC218CF8Q31157714-A0A1D864-3E4F-4CF5-80D7-79E803EDA494Q33378298-2DC5912E-B9DE-4C28-B426-1A61E0C1DEA5Q33392652-DAD65DAF-8C39-440F-9AFF-D55FEEE504DAQ33403848-B63581FD-4B48-468A-89D0-785B00C9784AQ33410746-94A54627-A1A9-49EC-A581-56221D639A5AQ33421880-8FA3CC6E-FB18-4A0B-BDB3-FF88DE3E7660Q33422258-FCDC0A44-0011-4D19-AB20-6CA736BE2821Q33424566-DC39B3A6-D1EF-45B7-A4FD-37B7624AC2AAQ33430813-BC06B44D-701F-4C1C-A8D3-9CA31DC8FBA5Q33506194-CB2EC23A-ABF9-4616-9511-840D7E0A5A8DQ33516882-23962441-F1F4-4A43-B5A2-F47F80FD8B2F
P2860
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Randomized phase III trial of ...... ated metastatic breast cancer.
@ast
Randomized phase III trial of ...... ated metastatic breast cancer.
@en
type
label
Randomized phase III trial of ...... ated metastatic breast cancer.
@ast
Randomized phase III trial of ...... ated metastatic breast cancer.
@en
prefLabel
Randomized phase III trial of ...... ated metastatic breast cancer.
@ast
Randomized phase III trial of ...... ated metastatic breast cancer.
@en
P2093
P356
P1476
Randomized phase III trial of ...... ated metastatic breast cancer.
@en
P2093
Amy P Sing
Beth A Overmoyer
Frankie A Holmes
Hope S Rugo
James D Reimann
Kathy D Miller
Linnea I Chap
Louis Fehrenbacher
Maura Dickler
Melody A Cobleigh
P304
P356
10.1200/JCO.2005.05.098
P407
P577
2005-02-01T00:00:00Z